Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Cont:
$10 million to Johnson & Johnson Innovation (JLABS) for a competition through Blue Knight, a BARDA-JLABS partnership.
The awards to BARDA’s Clinical Studies Network will speed the development of new vaccine candidates, providing a network of at-the-ready trials with the flexibility to pivot to the most promising new vaccines as they mature. The public can expect to see clinical trials for new vaccine candidates targeting longer-lasting protection against future variants as early as this winter under Project NextGen.
HHS’ partnership with Regeneron is advancing its efforts to prevent COVID-19 infections by developing a novel monoclonal antibody that will protect people who do not respond to or cannot take existing vaccines – a critical need and current gap in COVID-19 therapeutics. HHS and Regeneron expect that the new monoclonal antibody will enter clinical trials this fall.
The remaining awards will fund technologies that enable more efficient development and manufacturing strategies – accelerating development timelines across the board and bolstering future vaccine and therapeutic availability.
In parallel with the awards announced today, HHS continues to engage with potential partners and expects to announce additional awards before the end of this fiscal year.
If you would like to learn more about Project NextGen, please visit medicalcountermeasures.gov/nextgen/.
Maybe not directly linked to Synairgen, but interesting all the same:
Funding includes $1 billion for vaccine clinical trials, $326 million for a new monoclonal antibody, and $100 million to explore novel vaccine and therapeutic technologies
Today, the U.S. Department of Health and Human Services (HHS), through the Administration for Strategic Preparedness and Response (ASPR), awarded more than $1.4 billion for Project NextGen to support the development of a new generation of tools and technologies to protect against COVID-19 for years to come.
The awards announced today follow extensive coordination with industry partners and include support for clinical trials that will enable the rapid development of even more effective and longer-lasting coronavirus vaccines, a new monoclonal antibody, and transformative technologies to streamline manufacturing processes.
“Project NextGen is a key part of the Biden-Harris Administration’s commitment to keeping people safe from COVID-19 variants,” said HHS Secretary Xavier Becerra. “These awards are a catalyst for the program – kickstarting efforts to more quickly develop vaccines and continue to ensure availability of effective treatments.”
Project NextGen, a $5 billion initiative led by ASPR’s Biomedical Advanced Research and Development Authority (BARDA) in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), coordinates across the federal government and the private sector to advance innovative vaccines and therapeutics into clinical trials, regulatory review, and potential commercial availability for the American people. The project builds on a better understanding of COVID-19 – with HHS developing, using, and constantly re-evaluating the strengths and weaknesses of current vaccines and therapeutics for over three years.
“As the virus continues to evolve, we need new tools that keep pace with those changes,” said Assistant Secretary for Preparedness and Response Dawn O’Connell. “Project NextGen combines the research and development expertise at HHS with the lessons we have learned about the virus throughout the pandemic – strengthening our preparedness for whatever comes next.”
The awards announced today include the following actions:
$1 billion to four BARDA Clinical Trial partners to support vaccine Phase IIb clinical trial studies: ICON Government and Public Health Solutions, Inc of Hinckley, Ohio; Pharm-Olam, LLC, of Houston, Texas; Technical Resources Intl (TRI), Inc, of Bethesda, Maryland; and Rho Federal Systems, Inc., Durham, North Carolina.
$326 million to Regeneron to support the development of a next-generation monoclonal antibody for COVID-19 prevention.
$100 million to Global Health Investment Corp. (GHIC), the non-profit organization managing the BARDA Ventures investment portfolio to expand investments in new technologies that will accelerate responses in the future.
Unless there's a monumental balls-up, these P2 trails should show mind-blowing results, as Synairgen will have spent the best part of 18 months honing the trials to give the very best chance of success.
If this is the case then the SP *should* rise substantially making a fundraise more feasible (not sure what the "break-even" SP figure would be to determine feasibility..).
And you would expect that at this point it would be easier to find a funding partner, be it government or big pharma. At the AGM it was said many times that potential partners have previously asked for more data, so hopefully good data will indeed open the doors we hope it will.
The general feeling about Covid and/or the need for broad-spectrum antivirals at the time of the p2 results may also have a bearing on how things pan out. Let's hope Synairgens comms team do a good job of pushing home the merits of SNG001 upon successful results...
ATB & GLA
WOS. Your "headers" get more hilarious by the day...today's being a real "coffee spitter" after the pitiful 20 trades yesterday. Thank you for bringing some humour to this board and I look forward to the 30 bagger.
"Any day now!!!" BP.
Joking aside, it really is just a matter of patience. I'm not surprised this BB has gone a bit prickly lately...people get bored and impatient whilst there's a lack of information and frustrations surface. Hopefully things are progressing well behind the scenes and we'll get that positive red dot soon.
ATB & GLALTH.
Tomorrow!!!!!!!!!!!!!!!!!!!!!!
Monday!!!!!!!!!!!!!!!!!!!!!!!!!
In the coming days!!!!!!!!!!!!!!!!!!!!!!
Any day now!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
IMMANENTLY (pick appropriate incorrect spelling as the mood takes you)!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Hold tight folks.
ATB & GLA.
Patience, patience!! It does look like Doc had it bang on with his "around September" prediction a few months back.
Enjoy the summer weather and August will fly by....then we can start planning the 5p+ party.
R&H
I do acknowledge and appreciate your "not picking on the poster comment" but that being said I love this board and the way any comment which is not "with the narrative" gets picked up on instantly whereas the crap of "12-15p easy on LP", "hold tight the next RNS will have us upto 30p!!!", "10p by the end of the week" are applauded by everyone like demented clapping seals.
The SP clearly shows that no-one really gave a flying fig about the LP landing on its own, despite the cries of our so-call learned members with their lofty SP predictions. It's there in black and white.
So, although there is no " form of reasoning/ rational to the market or should I say MM's, almost as if its an "all seeing, all knowing" high calibre analyist weighing all data, propects and factors bhind the company inquestion or an analytical machine / specialist investment over lord."...
....the next RNS is going to be "explosive" and therefore I presume send the SP to orbit?!
What if it doesn't? I presume it will be the one after that?
Or the one after that?
These are the things the "nervous nellies" worry about. Me? - I'm probably the same as most here, happily invested and happy to be patient and wait for things to unfold.
ATB & GLA
HSD:
I just noticed there was a big price rise in mid-April. Can anybody tell me what happened?
This came out of the blue and then returned back quickly. Probably just MMs/Traders playing silly games
Also, what's the latest on Strive?
Two agents now on it, the 2nd of which they started recruitment for last week, about 3 months after its announcement. It was stated at the AGM that platform trials are on the back-burner now in favour of Synairgen's own studies, but if something viable was to come up (fully funded, with 1000s of patients ready to go for example) they would still consider it.
Have there been any significant changes regarding major shareholders (buys or sells) in the past few months?
None that I know of (no TR1s anyway).
It would be well worth you looking at the 2022 Full Year Report RNS and the posts on here straight after the AGM (30th June) as this will bring you up to date on the plans for the next year or so.
HTH & ATB.